Glucagon-like peptide-1 mimetics and sodium glucose contransporter-2 inhibitors, originally labeled to reduce hyperglycemia in patients with type 2 diabetes (T2D), are now incorporated into clinical practice guidelines in the US and Europe to reduce risk for or to treat common T2D comorbidities, including atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease.
Guidelines from the American Association of Clinical Endocrinology were recently updated with guidance on how to put the robust evidence from landmark clinical trial programs that support both classes into routine clinical practice.
AACE president and guideline coauthor Sethu Reddy, MD, spoke with Patient Care® about patient selection for the new indications among other key updates to the practice recommendations.
S Sethu K Reddy, MD, MBA, is the president of the American Association of Clinical Endocrinology and senior assocate dean of clinical research at Central Michigan University (CMU) College of Medicine, in Mount Pleasant, MI. Before joining CMU Reddy worked with the Cleveland Clinic in their endocrinology, diabetes and metabolism department for nearly 30 years.